(VIANEWS) – Krystal Biotech (KRYS), Sarepta Therapeutics (SRPT), Vital Farms (VITL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Krystal Biotech (KRYS)
127.5% sales growth and 14.2% return on equity
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Earnings Per Share
As for profitability, Krystal Biotech has a trailing twelve months EPS of $3.95.
PE Ratio
Krystal Biotech has a trailing twelve months price to earnings ratio of 45.45. Meaning, the purchaser of the share is investing $45.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.2%.
2. Sarepta Therapeutics (SRPT)
44.4% sales growth and 5.2% return on equity
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Earnings Per Share
As for profitability, Sarepta Therapeutics has a trailing twelve months EPS of $0.75.
PE Ratio
Sarepta Therapeutics has a trailing twelve months price to earnings ratio of 169.61. Meaning, the purchaser of the share is investing $169.61 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.2%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 69.6% and 174.5%, respectively.
Yearly Top and Bottom Value
Sarepta Therapeutics’s stock is valued at $127.21 at 16:22 EST, way below its 52-week high of $173.25 and way above its 52-week low of $55.25.
Moving Average
Sarepta Therapeutics’s worth is under its 50-day moving average of $137.59 and above its 200-day moving average of $126.61.
3. Vital Farms (VITL)
15.4% sales growth and 22.73% return on equity
Vital Farms, Inc. operates as an ethical food company in the United States. It produces five pasture-raised products sourced from animals raised on small family farms, including shell eggs, butter, hard-boiled eggs, ghee, and liquid whole eggs. The company's customers include natural retailers, mainstream retailers, and foodservice partners. Vital Farms, Inc. was founded in 2007 and is headquartered in Austin, Texas.
Earnings Per Share
As for profitability, Vital Farms has a trailing twelve months EPS of $1.06.
PE Ratio
Vital Farms has a trailing twelve months price to earnings ratio of 33.14. Meaning, the purchaser of the share is investing $33.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.73%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 30% and 5.9%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 38.5%, now sitting on 541.56M for the twelve trailing months.
Yearly Top and Bottom Value
Vital Farms’s stock is valued at $35.13 at 16:22 EST, way under its 52-week high of $48.41 and way higher than its 52-week low of $10.41.
Volume
Today’s last reported volume for Vital Farms is 826672 which is 13.16% below its average volume of 951996.
4. OFS Credit Company (OCCI)
12.2% sales growth and 10.34% return on equity
OFS Credit Company, Inc. is a fund of OFS Advisor.
Earnings Per Share
As for profitability, OFS Credit Company has a trailing twelve months EPS of $0.68.
PE Ratio
OFS Credit Company has a trailing twelve months price to earnings ratio of 11.07. Meaning, the purchaser of the share is investing $11.07 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.34%.
Yearly Top and Bottom Value
OFS Credit Company’s stock is valued at $7.53 at 16:22 EST, below its 52-week high of $7.81 and way higher than its 52-week low of $5.47.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3.1%, now sitting on 33.04M for the twelve trailing months.
Volume
Today’s last reported volume for OFS Credit Company is 123016 which is 48.58% below its average volume of 239263.
5. Stifel Financial Corporation (SF)
11.4% sales growth and 10.42% return on equity
Stifel Financial Corp., a financial services and bank holding company, provides retail and institutional wealth management, and investment banking services to individual investors, corporations, municipalities, and institutions in the United States and internationally. It operates in three segments: Global Wealth Management, Institutional Group, and Other. The company provides private client services, including securities transaction and financial planning services; institutional equity and fixed income sales, trading and research, and municipal finance services; investment banking services, such as mergers and acquisitions, public offerings, and private placements; and retail and commercial banking services comprising personal and commercial lending programs, as well as deposit accounts. It participates in and manages underwritings for corporate and public finance; and offers financial advisory and securities brokerage services. The company was founded in 1890 and is headquartered in Saint Louis, Missouri.
Earnings Per Share
As for profitability, Stifel Financial Corporation has a trailing twelve months EPS of $4.72.
PE Ratio
Stifel Financial Corporation has a trailing twelve months price to earnings ratio of 20. Meaning, the purchaser of the share is investing $20 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.42%.
Moving Average
Stifel Financial Corporation’s value is higher than its 50-day moving average of $86.63 and way above its 200-day moving average of $79.30.
6. International General Insurance Holdings Ltd. (IGIC)
11% sales growth and 21.7% return on equity
International General Insurance Holdings Ltd. provides specialty insurance and reinsurance solutions worldwide. The company operates through three segments: Specialty Long-tail, Specialty Short-tail, and Reinsurance segments. It offers a portfolio of specialty lines insurance products and services for energy, property, construction and engineering, ports and terminals, general aviation, political violence, casualty, financial institutions, marine liability, and treaty reinsurance. The company was founded in 2001 and is based in Amman, Jordan.
Earnings Per Share
As for profitability, International General Insurance Holdings Ltd. has a trailing twelve months EPS of $2.51.
PE Ratio
International General Insurance Holdings Ltd. has a trailing twelve months price to earnings ratio of 7.59. Meaning, the purchaser of the share is investing $7.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.7%.
7. Wintrust Financial Corporation (WTFC)
10.8% sales growth and 11.86% return on equity
Wintrust Financial Corporation operates as a financial holding company. It operates in three segments: Community Banking, Specialty Finance, and Wealth Management. The Community Banking segment offers non-interest bearing deposits, non-brokered interest-bearing transaction accounts, and savings and domestic time deposits; home equity, consumer, and real estate loans; safe deposit facilities; and automatic teller machine (ATM), online and mobile banking, and other services. It also engages in the retail origination and purchase of residential mortgages; and provision of lending, deposits, and treasury management services to condominium, homeowner, and community associations, as well as asset-based lending for middle-market companies. In addition, this segment offers loan and deposit services to mortgage brokerage companies; lending to restaurant franchisees; direct leasing; small business administration loans; commercial mortgages and construction loans; and financial solutions. It provides personal and commercial banking services primarily to individuals, small to mid-sized businesses, local governmental units, and institutional clients. The Specialty Finance segment offers commercial and life insurance premiums financing for businesses and individuals; accounts receivable financing, value-added, and out-sourced administrative services; other specialty finance services; equipment financing through structured loan and lease products; and property and casualty premium financing; as well as data processing of payrolls, billing, and cash management services to temporary staffing industry. The Wealth Management segment provides wealth management services, such as trust and investment, asset management, tax-deferred exchange, securities brokerage, and retirement plan services. Wintrust Financial Corporation was founded in 1991 and is headquartered in Rosemont, Illinois.
Earnings Per Share
As for profitability, Wintrust Financial Corporation has a trailing twelve months EPS of $9.61.
PE Ratio
Wintrust Financial Corporation has a trailing twelve months price to earnings ratio of 11.27. Meaning, the purchaser of the share is investing $11.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.86%.
Yearly Top and Bottom Value
Wintrust Financial Corporation’s stock is valued at $108.26 at 16:22 EST, under its 52-week high of $113.68 and way higher than its 52-week low of $71.86.
